190 related articles for article (PubMed ID: 21470180)
1. Recent developments of in silico predictions of oral bioavailability.
Zhu J; Wang J; Yu H; Li Y; Hou T
Comb Chem High Throughput Screen; 2011 Jun; 14(5):362-74. PubMed ID: 21470180
[TBL] [Abstract][Full Text] [Related]
2. Recent developments of in silico predictions of intestinal absorption and oral bioavailability.
Hou T; Li Y; Zhang W; Wang J
Comb Chem High Throughput Screen; 2009 Jun; 12(5):497-506. PubMed ID: 19519329
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
Paixão P; Gouveia LF; Morais JA
Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
[TBL] [Abstract][Full Text] [Related]
4. Structure-ADME relationship: still a long way to go?
Hou T; Wang J
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):759-70. PubMed ID: 18611116
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Oral Bioavailability in Rats: Transferring Insights from in Vitro Correlations to (Deep) Machine Learning Models Using in Silico Model Outputs and Chemical Structure Parameters.
Schneckener S; Grimbs S; Hey J; Menz S; Osmers M; Schaper S; Hillisch A; Göller AH
J Chem Inf Model; 2019 Nov; 59(11):4893-4905. PubMed ID: 31714067
[TBL] [Abstract][Full Text] [Related]
6. Improving on in-silico prediction of oral drug bioavailability.
Alqahtani S
Expert Opin Drug Metab Toxicol; 2023; 19(10):665-670. PubMed ID: 37728393
[TBL] [Abstract][Full Text] [Related]
7. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling of human oral bioavailability: what will be next?
Cabrera-Pérez MÁ; Pham-The H
Expert Opin Drug Discov; 2018 Jun; 13(6):509-521. PubMed ID: 29663836
[TBL] [Abstract][Full Text] [Related]
9. Animal versus human oral drug bioavailability: do they correlate?
Musther H; Olivares-Morales A; Hatley OJ; Liu B; Rostami Hodjegan A
Eur J Pharm Sci; 2014 Jun; 57(100):280-91. PubMed ID: 23988844
[TBL] [Abstract][Full Text] [Related]
10. Hologram QSAR model for the prediction of human oral bioavailability.
Moda TL; Montanari CA; Andricopulo AD
Bioorg Med Chem; 2007 Dec; 15(24):7738-45. PubMed ID: 17870541
[TBL] [Abstract][Full Text] [Related]
11. Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.
Kleppe MS; Forney-Stevens KM; Haskell RJ; Bogner RH
AAPS J; 2015 Jul; 17(4):902-17. PubMed ID: 25851513
[TBL] [Abstract][Full Text] [Related]
12. Advances in Predictions of Oral Bioavailability of Candidate Drugs in Man with New Machine Learning Methodology.
Fagerholm U; Hellberg S; Spjuth O
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925103
[TBL] [Abstract][Full Text] [Related]
13. Using in vitro and in vivo models to evaluate the oral bioavailability of nutraceuticals.
Ting Y; Zhao Q; Xia C; Huang Q
J Agric Food Chem; 2015 Feb; 63(5):1332-8. PubMed ID: 25615514
[TBL] [Abstract][Full Text] [Related]
14. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?
Hou T; Wang J; Zhang W; Xu X
J Chem Inf Model; 2007; 47(2):460-3. PubMed ID: 17381169
[TBL] [Abstract][Full Text] [Related]
15. Advances in computationally modeling human oral bioavailability.
Wang J; Hou T
Adv Drug Deliv Rev; 2015 Jun; 86():11-6. PubMed ID: 25582307
[TBL] [Abstract][Full Text] [Related]
16. Integration of In Silico Pharmacokinetic Modeling Approaches Into In Vitro Dissolution Profiles to Predict Bioavailability of a Poorly Soluble Compound.
Kato T; Watanabe T; Nakamura K; Ando S
J Pharm Sci; 2019 Nov; 108(11):3723-3728. PubMed ID: 31278915
[TBL] [Abstract][Full Text] [Related]
17. Impact of gastrointestinal disease states on oral drug absorption - implications for formulation design - a PEARRL review.
Effinger A; O'Driscoll CM; McAllister M; Fotaki N
J Pharm Pharmacol; 2019 Apr; 71(4):674-698. PubMed ID: 29766501
[TBL] [Abstract][Full Text] [Related]
18. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship.
Andrews CW; Bennett L; Yu LX
Pharm Res; 2000 Jun; 17(6):639-44. PubMed ID: 10955834
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
[TBL] [Abstract][Full Text] [Related]
20. In silico predictions of ADME-Tox properties: drug absorption.
Geerts T; Vander Heyden Y
Comb Chem High Throughput Screen; 2011 Jun; 14(5):339-61. PubMed ID: 21470183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
